Bone marrow histology in patients with a paroxysmal nocturnal hemoglobinuria clone correlated with clinical parameters
- 234 Downloads
Paroxysmal nocturnal hemoglobinuria (PNH) is a disease with variable presentation, including classical PNH (cPNH) and PNH with aplastic anemia (AA-PNH). Here, we describe bone marrow (BM) histology related to clinical findings in 67 patients with a PNH clone. Patients were divided in AA-PNH (n = 39) and cPNH (n = 28) based on clinical criteria and were compared to 17 AA patients without PNH clone. Median PNH clone size was higher in cPNH (75 %) than in AA-PNH (10 %) (p < 0.0001). BM cellularity was normal or increased in 65 % of cPNH, while it was decreased in AA-PNH and AA (95 % and 100 %) (p < 0.0001). Myelopoiesis and megakaryopoiesis were decreased in 85 % and 100 % of AA-PNH and 100 % of AA patients, but also in 86 % and 46 % of cPNH patients, even when peripheral blood values were normal. The percentage of CD59-deficient late-stage myeloid cells determined immunohistochemically correlated to PNH granulocyte clone size. Lymphoid nodules and increased mast cell numbers were present in all groups but more frequently in AA-PNH (38 % and 73 %) than in cPNH (20 % and 43 %). BM iron was decreased in 88 % of cPNH, while it was increased in AA-PNH (64 %) and AA (100 %) (p < 0.0001). Hemolysis was present in all cPNH but also in AA-PNH patients (67 %). In conclusion, cPNH patients had more cellular BM and more prominent erythropoiesis than AA-PNH patients. Nonetheless, cPNH patients also show AA features such as myeloid and megakaryocyte hypoplasia and inflammatory infiltrates, although more subtle than in AA-PNH. No significant differences were found between BM of AA patients with and without PNH clone.
KeywordsPNH Aplastic anemia Bone marrow failure Bone marrow histopathology
We thank all pathologists who have contributed to this study by providing BMB of patients with a PNH clone for revision and all hematologists who referred patients to us. Professor Dr Gérard Socié, Hôpital Saint Louis, Paris, is thanked for helpful advice.
Conflicts of interest
The authors declare that they have no conflict of interest.
- 2.Schrezenmeier H, Hertenstein B, Wagner B, Raghavachar A, Heimpel H (1995) A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. Exp Hematol 23(1):81–87PubMedGoogle Scholar
- 5.Wang SA, Pozdnyakova O, Jorgensen JL, Medeiros LJ, Stachurski D, Anderson M, Raza A, Woda BA (2009) Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica 94(1):29–37PubMedCrossRefGoogle Scholar
- 15.Gargiulo L, Lastraioli S, Cerruti G, Serra M, Loiacono F, Zupo S, Luzzatto L, Notaro R (2007) Highly homologous T-cell receptor beta sequences support a common target for autoreactive T cells in most patients with paroxysmal nocturnal hemoglobinuria. Blood 109(11):5036–5042PubMedCrossRefGoogle Scholar
- 19.Chen R, Nagarajan S, Prince GM, Maheshwari U, Terstappen LW, Kaplan DR, Gerson SL, Albert JM, Dunn DE, Lazarus HM, Medof ME (2000) Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria. J Clin Invest 106(5):689–696PubMedCrossRefGoogle Scholar
- 23.Schubert J, Hillmen P, Roth A, Young NS, Elebute MO, Szer J, Gianfaldoni G, Socie G, Browne P, Geller R, Rother RP, Muus P (2008) Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 142(2):263–272PubMedCrossRefGoogle Scholar
- 24.Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355(12):1233–1243PubMedCrossRefGoogle Scholar
- 25.(1987) Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study: Blood 70(6):1718–1721Google Scholar
- 30.Hernandez-Campo PM, Almeida J, Matarraz S, de Santiago M, Sanchez ML, Orfao A (2007) Quantitative analysis of the expression of glycosylphosphatidylinositol-anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow. Cytometry B Clin Cytom 72(1):34–42PubMedGoogle Scholar
- 31.Araten DJ, Swirsky D, Karadimitris A, Notaro R, Nafa K, Bessler M, Thaler HT, Castro-Malaspina H, Childs BH, Boulad F, Weiss M, Anagnostopoulos N, Kutlar A, Savage DG, Maziarz RT, Jhanwar S, Luzzatto L (2001) Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria. Br J Haematol 115(2):360–368PubMedCrossRefGoogle Scholar
- 38.Feng X, Chuhjo T, Sugimori C, Kotani T, Lu X, Takami A, Takamatsu H, Yamazaki H, Nakao S (2004) Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 104(8):2425–2431PubMedCrossRefGoogle Scholar
- 42.Takamatsu H, Feng X, Chuhjo T, Lu X, Sugimori C, Okawa K, Yamamoto M, Iseki S, Nakao S (2006) Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood 109(6):2514–2520Google Scholar
- 46.The Human Protein Atlas (http://www.proteinatlas.org/ENSG00000085063/normal/bone+marrow)